Clinical trial · Observational
Preventive Effects of Aspirin as Adjuvant Therapy in Patients With Locally Advanced Renal Cell Carcinoma
Preventive Effects of Low-dose Aspirin as Adjuvant Therapy After Radical Nephrectomy on Disease Recurrence/Metastasis and Survival in Patients With Locally Advanced Renal Cell Carcinoma: an Observational Prospective Cohort Study
NCT03734614CI-TRIAL-00035695unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study evaluates the protective effect of low-dose aspirin use as adjuvant therapy on locally advanced renal cell carcinoma in users and non-users of aspirin in Renji Hospital, Shanghai, China.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Aspirin as Adjuvant Therapy in Patients With Surgically Treated High Risk Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Low dose of aspirin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Patients with adjuvant aspirin
- description
- After surgery, patients would use low-dose aspirin (100mg) longer than 1 year
- interventionNames
- Drug: Low dose of aspirin
- label
- Patients without adjuvant aspirin
- description
- After surgery, patients would not use low-dose aspirin or use asprin shorter than 1 year
Primary outcomes (1)
- measure
- Disease-free Survival
- timeFrame
- 36 mouths
- description
- Disease-free Survival
Secondary outcomes (3)
- measure
- Overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must complete radical surgery more than 4 weeks and less than 12 weeks prior to study entry * Patients must have histologically or cytologically confirmed renal cell carcinoma. Using 2017 (American Joint Committee on Cancer \[AJCC\] 8th edition) TNM Staging, patients must be one of the following: * pT2aG3 or G4N0M0 * pT2bG(any)N0M0 * pT3G(any)N0M0 * pT4G(any)N0M0 * pT(any)G(any)N1M0 * Patients must have no clinical or imaging evidence of visible residual lesions or distant metastases (M0) after nephrectomy * Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Patients must be able to swallow pills Exclusion Criteria: * Patients with haemorrhagic diathesis (i.e. haemophilia). * Patients with prior malignant tumors except for kidney cancers in the past 5 years. * Patients with documented or suspected metastases. * Patients with serious, nonhealing wound, ulcer, or bone fracture. * Patients with a history of stroke, coronary arterial disease, angina, or vascular disease. * Patients who are pregnant, lactating, or not using adequate contraception. * Patients who have known allergy to NSAID or Aspirin. * Patients receiving other antiplatelet agents (i.e. clopidogrel, ticlopidine) or anticoagulants (i.e. warfarin, low molecular weight heparins). * Patients receiving current long term treatment (≥1 month) with Aspirin or other NSAIDs. * Subject unwilling or unable to comply with study requirements.
References
Publications (0)
Data not yet available
No reference posted for this study.